Elufoor - instructions for use, doses, side effects, contraindications

Excipients: sucrose - 1000.0 mg; sodium hydroxide 2.0 mg; methylparahydroxybenzoate 5.0 mg; carbomer - 10.5 mg; simethicone (emulsion 30%) - 10.5 mg; citric acid monohydrate 0.7 mg; flavored banana - 10.0 mg; water - up to 5 ml.

Description:

Suspension yellow, with a characteristic odor. A precipitate is allowed, a homogeneous suspension is formed after shaking.

Pharmacotherapeutic group:Antimicrobial agent

ATX: & nbsp

A.07.A.X.03 Nifuroxazide

Pharmacodynamics:

Nifuroxazide is an antimicrobial agent derived from nitrofuran.

Highly active in relation to Campylobacter jejuni, Escherichia coli, Salmonella spp., Shigella spp; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp.

Weakly sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae, Proteus indologenes.

Resistant to nifuroxazide: Klebsiella spp, Proteus mirabilis, Providencia spp., Pseudomonas spp.

Presumably blocks the activity of dehydrogenases and depresses respiratory chains, a cycle of tricarboxylic acids and a number of other biochemical processes in a microbial cell.

Does not disturb the balance of the intestinal microflora.

When acute bacterial diarrhea restores intestinal eubiosis.

When infected with enterotrophic viruses prevents the development of bacterial superinfection.

Pharmacokinetics:

After oral administration nifuroxazide practically not absorbed from the digestive tract, and its antibacterial action exerts exclusively in the lumen of the intestine. Nifuroxazide is excreted by the intestine: 20% unchanged, and the rest of the nifuroxazide is chemically altered.

Indications:

Acute bacterial diarrhea, proceeding without deterioration of the general condition, fever, intoxication.

Contraindications:

- Hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug;

- intolerance to fructose;

- glucose-galactose malabsorption syndrome or insufficiency of sucrose and isomaltase;

- pregnancy;

- period of newborns (up to 1 month), prematurity.

Pregnancy and lactation:

In studies on animals, there was no teratogenic effect. However, as a precautionary measure, nifuroxazide during pregnancy is not recommended.

During the lactation period, it is possible to continue breastfeeding in the case of a short course of treatment with the drug. It is necessary to consult a doctor.

Dosing and Administration:

It is applied inside.

For dispensing a dosage spoon with a volume of 5 ml, having a calibration of 2.5 ml is used.

Before use, the suspension should be shaken well.

Children from 1 to 6 months: 100 mg (2.5 ml) 2-3 times a day (the interval between doses is 8-12 hours).

Children from 6 months to 3 lay: 100 mg (2.5 ml) 3 times a day (the interval between meals is 8 hours).

Children from 3 to 6 years: 200 mg (5 ml) 3 times a day (the interval between doses is 8 hours).

Children from 6 to 18 years: 200 mg (5 ml) 3-4 times a day (the interval between doses is 6-8 hours).

Adults: 200 mg (5 ml) 4 times a day (the interval between doses is 6 hours).

The duration of the course of treatment is 5-7 days, but not more than 7 days. If there is no improvement within the first 3 days, you should consult a doctor.

Use the drug only according to the method of administration and the doses specified in the instructions. If necessary, please consult with your doctor before using the medication.

Side effects:

Allergic reactions (skin rash, urticaria, Quincke's edema, anaphylactic shock).

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor about it.

Overdose:

Symptoms of overdose are not known.

Treatment is symptomatic.

Interaction:

It is not recommended simultaneous use with drugs causing development of disulfiram-like reactions, drugs depressing the central nervous system.

If you are taking other medications (including over-the-counter drugs) before using Elufor, consult your doctor.

Special instructions:

When treating diarrhea concomitantly with nifuroxazide therapy, rehydration therapy should be performed.

Treatment of diarrhea in children under 3 years should be carried out under the supervision of a doctor.

In the case of bacterial diarrhea with signs of systemic damage (worsening of the general condition, fever, symptoms of intoxication or infection), consult a doctor to decide on the use ofantimicrobialof the systemic action.

In connection with the content of methyl parahydroxybenzoate, the drug may cause allergic reactions (possibly delayed).

During the treatment with the drug Elufror, alcohol is prohibited.

When symptoms of an allergic reaction appear (including shortness of breath, rash, itching), stop taking the drug.

Effect on the ability to drive transp. cf. and fur:

The drug does not affect the ability to drive vehicles and mechanisms.

Form release / dosage:Suspension for oral administration, 200 mg / 5 ml.

Packaging:

For 90 ml of the suspension in dark-colored bottles or bottles of polyethylene terephthalate, sealed with a lid of polyethylene or polypropylene with a control of the first opening or a screw cap with the control of the first opening.

A label is attached to the vial on the basis of a self-adhesive film.

Each bottle, along with instructions for use, as well as with a measuring spoon, is placed in a cardboard package (bundle).

It is allowed to bundle 2 or 3 cardboard packages (packs) into a group package (shipping container) from cardboard for consumer packaging.

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use the drug after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-004003

Date of registration:06.12.2016

Expiration Date:06.12.2021

The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia

Manufacturer: & nbsp

OZONE, LLC Russia

Representation: & nbspOZONE LLC OZONE LLC Russia

Information update date: & nbsp16.01.2017

Illustrated instructions

Instructions

Elufor (Elufor)